Skip to main content
. 2018 Aug 1;9(4):389–393. doi: 10.3892/mco.2018.1688

Figure 4.

Figure 4.

(A) Flow chart of patient selection for conversion surgery following gemcitabine plus nab-paclitaxel therapy in UR-LA PDAC. (B) The Kaplan-Meier survival curve revealed a favorable prognosis in conversion surgery group compared with the no conversion surgery group. *P=0.047, Wilcoxon test. UR-LA PDAC, locally advanced unresectable pancreatic ductal adenocarcinoma.